FX06

FX06 is a synthetic peptide derived from the N-terminal region of the fibrinogen beta chain (Bβ15–42). It acts as a competitive inhibitor of the binding of fibrin E1 fragments to vascular endothelial (VE)-cadherin, also known as Cadherin 5. By blocking this interaction, FX06 prevents leukocyte transmigration through the endothelial barrier and reduces tissue-damaging inflammation and capillary leak. This mechanism helps restore and maintain endothelial barrier function in conditions associated with increased vascular permeability. The drug has demonstrated anti-inflammatory and immunomodulatory properties in preclinical models of shock (septic, hemorrhagic), myocardial ischemia/reperfusion injury, and acute respiratory distress syndrome. Clinical development has focused on indications such as cardiac reperfusion injury/myocardial infarction, capillary leak syndrome including COVID-19-related ARDS, SARS-CoV-2 acute respiratory disease, and other vascular disorders[1][2][3][4][5][7]. The peptide is synthetically produced for human administration.

Other names

Fibrinogen beta chain (15-42)Bβ15-42